The purpose is to compare the clinical efficacy and toxicity of etoposide plus lobaplatin (EL) or etoposide plus cisplatin (EP) with concurrent thoracic radiotherapy during the treatment of limited-stage small cell lung cancer (LS-SCLC). Forty-two patients with LS-SCLC were randomly divided into EL (n = 19) or EP (n = 23) regimens combined with thoracic intensity-modulated radiotherapy. The primary endpoint was 1-year progression-free survival (PFS) rate. The 1-, 2-, and 3-year PFS rates in the EL and EP cohorts were 50.8, 38.1, and 12.7%; and 56.5, 43.5, and 29.0%, respectively (P = 0.527), whereas the 1-, 2-, and 3-year overall survival (OS) rates were 72.2, 52.5, and 43.8%; and 73.9, 48.4, and 48.4%, respectively (P = 0.923). The hematological toxicities were similar in two cohorts. However, gastrointestinal reactions were more severe in the EP group. The incidence of nausea and vomiting in EL and EP cohorts were 31.6% vs. 73.9% (P = 0.006) and 20.1% vs. 60.9% (P = 0.009), respectively. The two cohorts did not show ≥grade 4 radiation esophagitis and ≥grade 3 radiation pneumonitis. The incidence of acute radiation esophagitis in EL group was lower (P = 0.038), both groups showed a similar incidence of radiation pneumonitis (P = 1.000). EL or EP chemotherapy with concurrent thoracic radiotherapy showed similar PFS and OS. The EL group showed milder gastrointestinal toxicity and radiation esophagitis. Radiation pneumonitis and hematological toxicity were similar in the two regimens, which can be tolerated by patients.
ObjectiveTo investigate the alteration of subclinical lesions of subcutaneous xenograft tumors in nude mice after EGFR-TKI treatment. MethodsHuman lung adenocarcinoma cell lines were subcutaneously transplanted on the right hind legs of the nude mice in control and treatment groups. Three-dimensional pathological section was taken to observe the subclinical lesion areas when the tumors’ long diameters in the control group grew to specified length. In the Gefitinib treatment group, the subclinical lesions were observed likewise after tumor shrinkage. The results were compared. ResultsThe long diameters of transplanted tumors in group C were 5, 10, 15, and 20mm, the smallest infiltration range of subclinical lesions was 0.23, 0.78, 1.24, and 2.98mm. The edge of transplanted tumor was extended 5.14mm, to include 95% of subclinical lesions. The long diameter of the transplanted tumor in the T group shrank to 15, 10, 5, and 0mm, the smallest infiltration range was 5.74, 2.13, 2.13, and 0.11mm, the edge of the transplanted tumor was extended 8.99mm to include 95% of subclinical lesions. The extended range in T group was significantly larger than group C (P=0.000). ConclusionThe subclinical lesion receded after gefitinib treatment, but was wider than that of tumor of subclinical lesion without treatment. Even if the complete imaging response was achieved, there were still small infiltrating lesions.
Background and purpose Carbon ion is radiobiologically more effective than photons and are beneficial for treating radioresistant tumors, several animal experiment with tumor-bearing suggest that carbon ion beam irradiation in combination with immunotherapy yields better results, especially in controlling distant metastases, which suggests that carbon ion beam induces a different anti-tumor immune response than photon beam, more complex molecular mechanisms need to be further explored. We conduct this in vivo and in vitro experiment was to investigate the radio-immune effects and its mechanism of different LET rays combined PD-1 inhibitors.Methods and Materials: Lewis lung adenocarcinoma cells and C57BL/6 mice were stablished tumor-bearing mouse model, the irradiated tumor located on the left back and the non-irradiated tumor located on the right hind limb. The left back tumor was irradiated with 10Gy X-ray or carbon ion beam, combined with or without PD-1 inhibitor. Immunohistochemistry was used to detect the expression of immunogenicity-related molecules and the infiltration of CD8 + T cells in tumor tissues. ELISA was used to detect the changes of IFN-β in mouse serum, and flow cytometry was used to detect the changes of CD8 + T cells in mouse peripheral blood. Lewis cells were irradiated with different doses of X-ray and carbon ion. The changes of TREX1, PD-L1, and IFN-β in mRNA and protein levels were detected with RT-PCR or Western blot respectively. TREX1 knockdown were constructed by siRNA transfection and irradiated with different rays. Changes in cell proliferation, viability, apoptosis rate were detected using CCK8 assay, BrdU assay, and flow cytometry.Results X-ray or carbon ion combined with αPD-1 had a significant inhibitory effect on bilateral tumors, especially carbon ion in non-irradiated side tumor(p < 0.05). 10 Gy carbon ion irradiation enhanced the proportion of infiltrating CD8 + T cells and the expression level of IFN-β in irradiated side tumor, however, it also increased PD-L1 and TREX1 expression level. Lewis cell in vitro experiment further confirmed that both X-ray and carbon ion irradiation can up-regulate the expression levels of PD-L1 and TREX1 with dose-dependent in tumor, especially the trend of up-regulation TREX1 is more obvious at a higher dose in carbon ions, i.e 8 or 10Gy, while the level of IFN-βis decreased. By gene silencing TREX1, IFN-βlevels were also significantly increased under hypofractioned dose with carbon ion irradiation.Conclusions The combination of X-ray or carbon ion irradiation and PD-1 inhibitors produce better anti-tumor effect and trigger abscopal effect on Lewis lung adenocarcinoma bearing mice through enhanced tumor immunogenicity and increased CD8 + T infiltration in TME via a threshold dose. TREX1 could serve as a prognostic marker and potential target of immunotherapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.